Morphological, immunohistochemical, and molecular methods often need to be combined for accurate diagnosis and optimal clinical management of
sarcomas. Here, we have developed, a new molecular diagnostic assay, for the detection of gene fusions in
sarcomas. This targeted multiplexed next-generation sequencing (NGS)-based method utilizes
ligation dependent
reverse-transcriptase polymerase chain reaction (LD-RT-PCR-NGS) to detect oncogenic fusion transcripts involving 137 genes, leading to 139 gene fusions known to be recurrently rearranged in soft-tissue and bone
tumors. 158 bone and soft-tissue
tumors with previously identified fusion genes by fluorescent in situ hybridization (FISH) or RT-PCR were selected to test the specificity and the sensitivity of this assay.
RNA were extracted from
formalin-fixed
paraffin-embedded (n = 143) or frozen (n = 15) material (specimen; n = 42 or core needle biopsies; n = 116). Tested
tumors encompassed 23 major translocation-related
sarcomas types, including Ewing and Ewing-like
sarcomas,
rhabdomyosarcomas, desmoplastic small round-cell
tumors,
clear-cell sarcomas, infantile
fibrosarcomas,
endometrial stromal sarcomas,
epithelioid hemangioendotheliomas, alveolar soft-part
sarcomas, biphenotypic sinonasal
sarcomas, extraskeletal myxoid
chondrosarcomas, myxoid/
round-cell liposarcomas,
dermatofibrosarcomas protuberans and
solitary fibrous tumors. In-frame fusion transcripts were detected in 98.1% of cases (155/158). Gene fusion assay results correlated with conventional techniques (FISH and RT-PCR) in 155/158
tumors (98.1%). These data demonstrate that this assay is a rapid, robust, highly sensitive, and multiplexed targeted
RNA sequencing assay for the detection of recurrent gene fusions on
RNA extracted from routine clinical specimens of
sarcomas (
formalin-fixed
paraffin-embedded or frozen). It facilitates the precise diagnosis and identification of
tumors with potential targetable fusions. In addition, this assay can be easily customized to cover new fusions.